Samsara Therapeutics

The company's business model is centered on the discovery and development of small molecule drugs that can activate autophagy, the body's natural mechanism for clearing out damaged cells and dysfunctional proteins. Revenue generation is anticipated through the successful clinical development and subsequent commercialization of its therapeutic pipeline, partnerships with larger pharmaceutical companies, and licensing agreements. A significant milestone was achieved in late 2019 when the company secured $3.2 million in a seed funding round, which included investors like Cambrian BioPharma and Kite Ventures, following an initial pre-seed investment from Apollo Health Ventures. By 2021, Samsara had raised a total of $16 million. The company collaborates with patient foundations, such as the CMT Research Foundation, to advance its drug candidates toward clinical trials.

Samsara Therapeutics' core technology is its proprietary drug discovery platform, which includes the Lysoseeker™ platform and other high-throughput, cell-based screening technologies. This platform is designed to identify and validate small molecules that can modulate autophagy. A key differentiator is the use of phenotypic screening in disease-relevant, patient-derived induced pluripotent stem cells (iPSCs), which allows for testing in human cells from the outset. The company has built a portfolio of drug programs targeting various neurodegenerative conditions. Its lead candidate, SAM001, is being developed for Amyotrophic Lateral Sclerosis (ALS) and has shown the ability to reverse disease symptoms in mice by targeting the TRPML1 protein. Other programs include SAM0021 for Parkinson's Disease and candidates for Charcot-Marie-Tooth (CMT) disease, focusing on different stages of the autophagy pathway like autophagosome formation and lysosomal biogenesis.